European Strategy or American Strategy: First Immunosuppression in Rapidly Progressive Antisynthetase-ILD
A physical therapist's new, rapidly worsening antisynthetase-syndrome lung disease sits between two named treatment traditions that a purpose-built trial has never finished comparing.
E.V., a 47-year-old physical therapist, first noticed the skin on the pads of her fingers cracking and thickening in a way that had nothing to do with the hand sanitizer she blamed at first — mechanic's hands, her rheumatologist called it the day the diagnosis came together. Over three weeks, arthralgia in her wrists and mild proximal weakness climbing stairs joined a cough and breathlessness that got materially worse week to week rather than settling. Anti-Jo-1 antibody came back strongly positive, creatine kinase was mildly elevated, and a same-week HRCT showed a nonspecific interstitial pneumonia pattern with rapidly progressive ground-glass change compared to an outside scan obtained only eleven days earlier. Her FVC has already dropped from 78% to 64% predicted in that same short window — real, fast movement, not the months-long drift most interstitial lung disease follows.
Antisynthetase syndrome-associated interstitial lung disease has two named treatment traditions and, honestly, no completed trial deciding between them. The so-called European strategy uses intravenous cyclophosphamide followed by azathioprine maintenance; the American strategy starts with tacrolimus. CATR-PAT, the randomized phase III trial designed specifically to compare the two, has never published a result settling the question either way. What exists instead is retrospective: a French cohort found intravenous cyclophosphamide produced better functional lung outcomes than other agents in myositis-ILD broadly, while Wilkes and colleagues, reviewing fifteen U.S. patients with antisynthetase-associated ILD treated with tacrolimus, found significant improvement in pulmonary function across the series — numbers describing two different, uncontrolled populations rather than a real comparison. The Wilkes patients matter less to E.V. than they first appear: every one of them had already failed conventional therapy, and she has had none. The tacrolimus evidence is a salvage record, and she is not yet a salvage patient. For E.V. specifically, the fact her decline is measured in weeks rather than months is the detail the room actually has to weigh, since neither retrospective series was built to say which drug acts faster. Her creatine kinase, only mildly elevated despite visible muscle weakness, is itself a small piece of that puzzle — a pattern more typical of antisynthetase-associated myositis than of classic polymyositis, and one several of the same case series flag as tracking poorly with how aggressive the accompanying lung disease turns out to be.
Two named strategies, no trial to choose between them
Start intravenous cyclophosphamide. Moreno-Torres and colleagues found IV cyclophosphamide produced better functional lung outcomes than other immunosuppressive agents in myositis-associated ILD — the most direct functional evidence available, and E.V.'s decline is moving fast enough that I want the agent with the strongest functional signal, not the gentlest one.
You're right that cyclophosphamide's functional data in severe myositis-ILD is real. But Wilkes and colleagues found significant pulmonary function improvement across their whole tacrolimus series, with real steroid-sparing benefit and none of cyclophosphamide's cytopenia, infertility, or infection risk — and CATR-PAT exists precisely because nobody has actually proven cyclophosphamide superior to it.
“Better functional outcomes than other agents” in one uncontrolled French cohort isn't the same claim as cyclophosphamide beating tacrolimus specifically — that comparison is the exact trial that's never finished.
Neither retrospective series was built to answer a speed-of-onset question, and that's the actual fact in front of us: her FVC dropped fourteen points in eleven days. Intravenous cyclophosphamide's track record in the most severe, fastest-moving myositis-ILD literature specifically argues for its onset here, with tacrolimus as the calmer maintenance step once the acute trajectory is controlled — not a claim that one strategy is generally superior.
Agreed: begin intravenous cyclophosphamide now given the pace of her decline, with a plan to transition to azathioprine maintenance once stabilized.
Not agreed: whether tacrolimus should have been the starting point instead had her decline been slower — the pulmonologist believes tacrolimus remains the better default outside a genuinely rapid presentation like this one; the rheumatologist is not convinced tempo alone should decide it.